SciRhom receives 63 million euros in Series A financing round

SciRhoma Munich-based biopharmaceutical company developing therapeutic iRhom2 antibodies has raised EUR 63 million in its Series A financing round.

The round was co-led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital and Wellington Partners, with participation from new investor Bayern Kapital and existing investors including High-Tech Gründerfonds (HTGF) and PhiFund Ventures from New York, USA.

In connection with this investment, Dr. Olivier Litzka of Andera Partners, Dr. Peter Neubeck of Kurma Partners, Dr. Georgina Askeland of Hadean Ventures, Dr. Fei Tian of MIG Capital and Dr. Varun Gupta of Wellington Partners will join SciRhom’s Board of Directors.

The company intends to use the funds to accelerate and expand the impact of its therapeutic strategy in autoimmune diseases.

SciRhom offers proprietary iRhom2-targeted therapies and is advancing its lead antibody program SR-878 through clinical development. Based on positive preclinical data sets generated in vitro and in established animal models of rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), the company has advanced its first program to a Phase 1-ready stage. As announced on June 12, 2024, the first CTA approval was granted, paving the way for the initiation of a first clinical trial in Austria in the second half of 2024. The aim of the study is to evaluate safety in healthy volunteers and to provide initial evidence of clinical activity in the second part of the study.

The management team includes:

• Dr. Jens Ruhe, Managing Director and COO,
• Dr. Jan Poth, Managing Director and CEO, and
• Dr. Matthias Schneider, CSO.

FinSMEs

09.07.2024